Rat Models of Bone Metastases
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 22 (8) , 605-614
- https://doi.org/10.1007/s10585-006-9002-5
Abstract
Bone metastases occur frequently in patients with advanced breast or prostate cancer. Bone metastases can be predominantly osteolytic, osteoblastic or mixed. Studies with animal models allow advances in understanding the molecular basis for bone metastases and provide new targets for therapy. Several animal models have been developed in rat with different pathophysiologies; they required injection or implantation of neoplastic cells into orthotopic locations, bones or the left ventricle of the heart. Several specific strains of rat have an increased incidence of spontaneous tumors. Carcinomas can be induced by either chemicals or physical agents. However, the most used and convenient way to induce bone metastases is a syngeneic transmission. MAT-Ly-Lu cells have been used in several models using Copenhagen rats to induce osteoblastic bone lesions. PA-III cells derived from Pollard tumors can also produce a combination of osteolytic and osteoblastic reactions at the site of transplantation. Osteolytic bone lesions can be obtained with an injection of Walker cells. The use of 13762 or c-SST2 cells allows also leads to osteolysis. Human xenografts can only be used in nude animals. It is essential to validate and correctly interpret the lesions in several models of bone metastasis. No animal model is sufficient by itself to represent the clinical findings observed in humans. The use of models developed in different species should be more predictive and bring a beam of arguments for a better knowledge of pathophysiological and therapeutic mechanisms.Keywords
This publication has 80 references indexed in Scilit:
- The multiple uses of fluorescent proteins to visualize cancer in vivoNature Reviews Cancer, 2005
- Characterization of a rat model with site‐specific bone metastasis induced by MDA‐MB‐231 breast cancer cells and its application to the effects of an antibody against bone sialoproteinInternational Journal of Cancer, 2005
- Osteoblasts in prostate cancer metastasis to boneNature Reviews Cancer, 2005
- Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone ResorptionThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Site‐specific human breast cancer (MDA‐MB‐231) metastases in nude rats: Model characterisation and in vivo effects of ibandronate on tumour growthInternational Journal of Cancer, 2003
- Role of stromal-derived cytokines and growth factors in bone metastasisCancer, 2003
- Influence of flexible nailing in the later phase of fracture healing: strength and mineralization in rat femoraJournal of Orthopaedic Science, 2001
- Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysisLife Sciences, 1997
- Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat modelSurgical Oncology, 1996
- Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcomaLife Sciences, 1995